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Abstract 28 
Using 894 phylogenetically diverse genomes of the Mycobacterium tuberculosis complex (MTBC), we 29 
simulated in silico the ability of the Hain Lifescience GenoType MTBC to differentiate the causative 30 
agents of tuberculosis. We propose a revised interpretation of this assay to reflect its strengths (e.g. 31 
it can distinguish some strains of M. canettii and variants of M. bovis that are not intrinsically 32 
resistant to pyrazinamide) and limitations (e.g. M. orygis cannot be differentiated from M. 33 
africanum). 34 
 35 
Manuscript 36 
The IVD-CE marked Hain Lifescience GenoType MTBC is the oldest and likely most widely used 37 
commercial assay to differentiate the causative agents of tuberculosis (TB) (1). Strictly speaking, 38 
these comprise Mycobacterium canettii, which is almost exclusively limited to the Horn of Africa, on 39 
the one hand and several species/ecotypes of the M. tuberculosis complex (MTBC) on the other, 40 
although most researchers and guidelines consider M. canettii to be part of the MTBC (2, 3). 41 
Clinically, the early identification of the precise causative agent of TB is important because it can 42 
serve as a marker for intrinsic resistance or may inform the attribution of the source of infection 43 
(e.g. in case of M. bovis, intrinsic resistance to pyrazinamide can usually be ruled in and a human 44 
source for the infection is unlikely (4)). 45 
 Throughout the past decade, the interpretation of the GenoType MTBC, but not its design, 46 
has been revised to reflect changes in our understanding of the causative agents of TB (1, 3, 5). More 47 
recently, several new animal species/ecotypes have been discovered, which prompted us to 48 
investigate to what extent these could be differentiated with the Hain assay using a collection of 894 49 
diverse genomes representing M. canettii and major phylogenetic groups of MTBC (Figure S1 and 50 
Table S1) (6). This was possible because Hain Lifescience has filed a European patent (EP1490518B1) 51 
for its assay, which relies on a 23 rRNA probe to identify M. canettii/MTBC as a whole, whereas 52 
mutations in gyrB and the RD1BCG deletion differentiate individual species/ecotypes (Figures S1 and 53 
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S2 and Table S2 (7)). Specifically, we typed all 894 genomes in silico for the SNP and deletion markers 54 
from the patent (Supplemental methods). 55 
 The current package insert of the GenoType MTBC lists seven binding patterns for M. 56 
canettii or MTBC isolates (patterns 2-8 in Figure 1 and Table S1). In 2010, however, Fabre et al. 57 
demonstrated experimentally that a minority of M. canettii strains yield a novel pattern, which does 58 
not feature in the package insert (8). Our simulation confirmed these results. Specifically, two of the 59 
M. canettii strains with the unusual experimental pattern (i.e. Percy157 and Percy525) from Fabre et 60 
al., for which genomes were available and, therefore, could be included in our study, also yielded 61 
the novel pattern in silico (pattern 1 in Figure 1 and Table S1) (8). The remaining five M. canettii 62 
genomes from Fabre et al. (i.e. Percy22, Percy32, Percy50, Percy79, and Percy301) could not be 63 
differentiated from M. tuberculosis in silico, which was in agreement with the experimental findings 64 
(pattern 2 in Figure 1 and Table S1) (8). Given the highly recombinogenic nature of M. canettii, it is 65 
not surprising that this species yields two different patterns (9, 10). All representatives of this 66 
species, including the two strains that gave the new binding pattern experimentally and in silico, 67 
have been found to be resistant to pyrazinamide when tested with the BACTEC MGIT 960 at 100 68 
g/ml, the only critical concentration recognized by the Clinical and Laboratory Standards Institute 69 
and the World Health Organization (8, 11-16). Although it is unclear whether this phenotype is due 70 
to a single mechanism shared by all strains (e.g. rpsA T5A) or whether different mutations are 71 
responsible in different strains (e.g. panD M117T or a series of pncA mutations (Table S3)), we 72 
recommend that the package insert is updated to include this novel pattern as “M. canettii 73 
(intrinsically resistant to pyrazinamide)” (13, 17-19). 74 
Moreover, our findings suggest the following changes for the remaining seven binding 75 
patterns (Figure 1 and S1 and Table S1). First, pattern 3, currently used to differentiate M. africanum 76 
from the rest of the MTBC and M. canettii, has to be revised since our analysis showed this pattern 77 
cannot distinguish M. africanum from M. orygis, M. pinnipedii, nor the clade A1 ecotypes (i.e. M. 78 
mungi, M. suricattae, the chimpanzee bacillus, and the dassie bacillus) (6, 20, 21). Second, for the 79 
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sake of clarity we would separate M. bovis and M. caprae as they belong to two independent 80 
phylogenetic groups and are usually recognised as separate species/ecotypes (3). By contrast, BCG 81 
was derived from a M. bovis strain and is best described as M. bovis BCG to emphasize its intrinsic 82 
resistance to pyrazinamide (4). Finally, the current package insert features two binding patterns for 83 
“M. bovis subsp. caprae”, of which one is described to occur in only 5% of cases of M. caprae (5). 84 
Our collection featured seven genomes consistent with this rarer pattern. However, the seven 85 
genomes did not group together phylogenetically (Figure S1). Three of the strains were isolated in 86 
2009 from primates that were placed in quarantine upon entering the United States (22, 23). Their 87 
genomes grouped together with the M. caprae genomes on the phylogeny and shared the lepA 88 
V424V marker for this species (24). By contrast, the other four genomes were more closely related 89 
to M. bovis, but lacked the pncA H57D mutation that is responsible for intrinsic pyrazinamide 90 
resistance in this species (7, 13). Three of these isolates were isolated from humans in Malawi and 91 
the fourth from an antelope in Germany. For the latter sample, we knew the spoligotyping pattern, 92 
which we used to query the M. bovis spoligotype database (25). The spoligotype for the antelope 93 
isolate from 1996 (SB1898) appears to be very rare as only one identical representative was found, 94 
which was submitted from Spain in 2009. Thus, it is unclear whether these four strains represent a 95 
novel ecotype or species, but, because they are phylogenetically closer to M. bovis than M. caprae, 96 
we recommend that pattern 6 should be reported as “M. caprae/M. bovis (not intrinsically resistant 97 
to pyrazinamide)”.  98 
M. orygis has been isolated from many different animals and there is a growing recognition 99 
that it is a zoonotic source of human TB (26). Our in silico typing approach confirmed that M. orygis 100 
could be specifically identified by a mutation at codon 329 of gyrB (7). Since this marker is contained 101 
within the gyrB amplicon, we suggest it could be added to the Hain assay, as this would avoid 102 
misclassifications, such as in Rahim et al. in which cattle from Bangladesh were erroneously reported 103 
to have been infected with M. africanum instead of M. orygis (27). 104 
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 The findings in this study are important for two reasons. First, most of our proposed changes 105 
can be implemented easily by updating the package insert of the Hain Lifescience GenoType MTBC 106 
(5). More broadly, given that whole-genome sequencing is now increasingly being used as a routine 107 
diagnostic tool, it would be possible to implement our in silico surveillance approach in real time to 108 
automatically flag unusual isolates for experimental follow-up. In fact, if clinical sequencing 109 
providers, such as Public Health England in the United Kingdom, were to offer this as a professional 110 
service, it could generate much-needed revenue to reduce the cost of sequencing to public health 111 
systems and, therefore, the tax payer, whilst enabling commercial companies to conduct post-112 
marketing surveillance for genotypic assays comprehensively and cost-effectively – a win-win 113 
situation for all parties.  114 
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Figure 1. Proposed interpretation of binding patterns of Hain Lifescience GenoType MTBC. 115 
Eight binding patterns are possible for samples that contain a single strain of MTBC or M. canettii. 116 
The first binding pattern is not currently included in the package insert of the GenoType MTBC (5, 8). 117 
With the exception of pattern 4 for M. microti, the interpretations of the remaining patterns were 118 
updated to include information about intrinsic resistance to antibiotics and/or to reflect the 119 
improved understanding of the phylogenetic diversity amongst the causative agents of TB. More 120 
information about clade A1 can be found elsewhere (6). Additional binding patterns are possible for 121 
samples that are negative, contain other bacteria, or when the assay was not carried out correctly 122 
(in these cases one or more of the conjugate control (CC), universal control (UC), or MTBC bands 123 
would be negative (5)). 124 
   125 
 o
n
 M
ay 13, 2019 by guest
http://aac.asm
.org/
D
ow
nloaded from
 
  8 
Funding 126 
F.C. received support from the Wellcome Trust (201344/Z/16/Z). S.N. received support from the 127 
German Center for Infection Research, the Deutsche Forschungsgemeinschaft (DFG, German 128 
Research Foundation) under Germany’s Excellence Strategy (EXC 22167-390884018), and the Leibniz 129 
Science Campus EvoLUNG (Evolutionary Medicine of the Lung). S.G. was supported by the Swiss 130 
National Science Foundation (grants 310030_166687, IZRJZ3_164171, IZLSZ3_170834, and 131 
CRSII5_177163), the European Research Council (309540-EVODRTB), and SystemsX.ch. The funders 132 
had no role in the study design, data collection, interpretation, or the decision to submit the work 133 
for publication. 134 
 135 
Acknowledgement 136 
Calculations were performed at sciCORE (http://scicore.unibas.ch/) scientific computing core facility 137 
at University of Basel. 138 
 139 
Conflicts of interest 140 
F.C. received personal fees from Next Gen Diagnostics LLC. S.J.P. is a consultant for Next Gen 141 
Diagnostics and Specific. C.U.K. is a consultant for the World Health Organization (WHO) Regional 142 
Office for Europe, QuantuMDx Group Ltd., and the Foundation for Innovative New Diagnostics, 143 
which involves work for the Cepheid Inc., Hain Lifescience, and WHO. C.U.K. is an advisor to 144 
GenoScreen. The Bill & Melinda Gates Foundation, Janssen Pharmaceutica, and PerkinElmer covered 145 
C.U.K.’s travel and accommodation to present at meetings. The Global Alliance for TB Drug 146 
Development Inc. and Otsuka Novel Products GmbH have supplied C.U.K. with antibiotics for in vitro 147 
research. C.U.K. is collaborating with YD Diagnostics.  148 
 o
n
 M
ay 13, 2019 by guest
http://aac.asm
.org/
D
ow
nloaded from
 
  9 
References 149 
1. Richter E, Weizenegger M, Rüsch-Gerdes S, Niemann S. 2003. Evaluation of genotype MTBC 150 
assay for differentiation of clinical Mycobacterium tuberculosis complex isolates. J Clin 151 
Microbiol 41:2672-5. 152 
2. Clinical and Laboratory Standards Institute. M48. Laboratory detection and identification of 153 
mycobacteria, 2nd edition. 154 
3. Gagneux S. 2018. Ecology and evolution of Mycobacterium tuberculosis. Nat Rev Microbiol 155 
16:202-213. 156 
4. Köser CU, Feuerriegel S, Summers DK, Archer JA, Niemann S. 2012. Importance of the 157 
genetic diversity within the Mycobacterium tuberculosis complex for the development of 158 
novel antibiotics and diagnostic tests of drug resistance. Antimicrob Agents Chemother 159 
56:6080-7. 160 
5. Hain Lifescience. GenoType MTBC VER 1.X. Instructions for use IFU-301-11. 12/2017. 161 
6. Brites D, Loiseau C, Menardo F, Borrell S, Boniotti MB, Warren R, Dippenaar A, Parsons SDC, 162 
Beisel C, Behr MA, Fyfe JA, Coscolla M, Gagneux S. 2018. A new phylogenetic framework for 163 
the animal-adapted Mycobacterium tuberculosis complex. Front Microbiol 9:2820. 164 
7. Huard RC, Fabre M, de Haas P, Lazzarini LC, van Soolingen D, Cousins D, Ho JL. 2006. Novel 165 
genetic polymorphisms that further delineate the phylogeny of the Mycobacterium 166 
tuberculosis complex. J Bacteriol 188:4271-87. 167 
8. Fabre M, Hauck Y, Soler C, Koeck JL, van Ingen J, van Soolingen D, Vergnaud G, Pourcel C. 168 
2010. Molecular characteristics of "Mycobacterium canettii" the smooth Mycobacterium 169 
tuberculosis bacilli. Infect Genet Evol 10:1165-73. 170 
9. Supply P, Marceau M, Mangenot S, Roche D, Rouanet C, Khanna V, Majlessi L, Criscuolo A, 171 
Tap J, Pawlik A, Fiette L, Orgeur M, Fabre M, Parmentier C, Frigui W, Simeone R, Boritsch EC, 172 
Debrie AS, Willery E, Walker D, Quail MA, Ma L, Bouchier C, Salvignol G, Sayes F, Cascioferro 173 
A, Seemann T, Barbe V, Locht C, Gutierrez MC, Leclerc C, Bentley SD, Stinear TP, Brisse S, 174 
 o
n
 M
ay 13, 2019 by guest
http://aac.asm
.org/
D
ow
nloaded from
 
  10 
Medigue C, Parkhill J, Cruveiller S, Brosch R. 2013. Genomic analysis of smooth tubercle 175 
bacilli provides insights into ancestry and pathoadaptation of Mycobacterium tuberculosis. 176 
Nat Genet 45:172-9. 177 
10. Boritsch EC, Khanna V, Pawlik A, Honore N, Navas VH, Ma L, Bouchier C, Seemann T, Supply 178 
P, Stinear TP, Brosch R. 2016. Key experimental evidence of chromosomal DNA transfer 179 
among selected tuberculosis-causing mycobacteria. Proc Natl Acad Sci U S A 113:9876-81. 180 
11. Somoskovi A, Dormandy J, Mayrer AR, Carter M, Hooper N, Salfinger M. 2009. 181 
"Mycobacterium canettii" isolated from a human immunodeficiency virus-positive patient: 182 
first case recognized in the United States. J Clin Microbiol 47:255-7. 183 
12. Koeck JL, Fabre M, Simon F, Daffé M, Garnotel E, Matan AB, Gérôme P, Bernatas JJ, Buisson 184 
Y, Pourcel C. 2011. Clinical characteristics of the smooth tubercle bacilli 'Mycobacterium 185 
canettii' infection suggest the existence of an environmental reservoir. Clin Microbiol Infect 186 
17:1013-1019. 187 
13. Feuerriegel S, Köser CU, Richter E, Niemann S. 2013. Mycobacterium canettii is intrinsically 188 
resistant to both pyrazinamide and pyrazinoic acid. J Antimicrob Chemother 68:1439-40. 189 
14. Blouin Y, Cazajous G, Dehan C, Soler C, Vong R, Hassan MO, Hauck Y, Boulais C, 190 
Andriamanantena D, Martinaud C, Martin E, Pourcel C, Vergnaud G. 2014. Progenitor 191 
"Mycobacterium canettii" clone responsible for lymph node tuberculosis epidemic, Djibouti. 192 
Emerg Infect Dis 20:21-8. 193 
15. Bouzid F, Astier H, Osman DA, Javelle E, Hassan MO, Simon F, Garnotel E, Drancourt M. 194 
2018. Extended spectrum of antibiotic susceptibility for tuberculosis, Djibouti. Int J 195 
Antimicrob Agents 51:235-238. 196 
16. Briquet A, Vong R, Roseau JB, Javelle E, Cazes N, Riviere F, Aletti M, Otto MP, Ficko C, Duron 197 
S, Fabre M, Pourcel C, Simon F, Soler C. 2019. Clinical features of Mycobacterium canettii 198 
infection: a retrospective study of 20 cases among French soldiers and relatives. Clin Infect 199 
Dis doi:10.1093/cid/ciz107:ahead of print. 200 
 o
n
 M
ay 13, 2019 by guest
http://aac.asm
.org/
D
ow
nloaded from
 
  11 
17. Alexander DC, Ma JH, Guthrie JL, Blair J, Chedore P, Jamieson FB. 2012. Gene 201 
sequencing for routine verification of pyrazinamide resistance in Mycobacterium 202 
tuberculosis: a role for pncA but not rpsA. J Clin Microbiol 50:3726-8. 203 
18. Zhang S, Chen J, Shi W, Liu W, Zhang W, Zhang Y. 2013. Mutations in panD encoding 204 
aspartate decarboxylase are associated with pyrazinamide resistance in Mycobacterium 205 
tuberculosis. Emerg Micro Infect 2:e34. 206 
19. Shi W, Cui P, Niu H, Zhang S, Tonjum T, Zhu B, Zhang Y. 2019. Introducing RpsA point 207 
mutations Δ438A and D123A into the chromosome of M. tuberculosis confirms their role in 208 
causing resistance to pyrazinamide. Antimicrob Agents Chemother doi:10.1128/AAC.02681-209 
18:ahead of print. 210 
20. Kjeldsen MK, Bek D, Rasmussen EM, Priemé A, Thomsen V. 2009. Line probe assay for 211 
differentiation within Mycobacterium tuberculosis complex. Evaluation on clinical specimens 212 
and isolates including Mycobacterium pinnipedii. Scand J Infect Dis 41:635-41. 213 
21. van Ingen J, Rahim Z, Mulder A, Boeree MJ, Simeone R, Brosch R, van Soolingen D. 2012. 214 
Characterization of Mycobacterium orygis as M. tuberculosis complex subspecies. Emerg 215 
Infect Dis 18:653-5. 216 
22. Joshi D, Harris NB, Waters R, Thacker T, Mathema B, Krieswirth B, Sreevatsan S. 2012. Single 217 
nucleotide polymorphisms in the Mycobacterium bovis genome resolve phylogenetic 218 
relationships. J Clin Microbiol 50:3853-61. 219 
23. Orloski K, Robbe-Austerman S, Stuber T, Hench B, Schoenbaum M. 2018. Whole genome 220 
sequencing of Mycobacterium bovis isolated from livestock in the United States, 1989-2018. 221 
Front Vet Sci 5:253. 222 
24. Domogalla J, Prodinger WM, Blum H, Krebs S, Gellert S, Muller M, Neuendorf E, Sedlmaier F, 223 
Buttner M. 2013. Region of difference 4 in Alpine Mycobacterium caprae isolates indicates 224 
three variants. J Clin Microbiol 51:1381-8. 225 
 o
n
 M
ay 13, 2019 by guest
http://aac.asm
.org/
D
ow
nloaded from
 
  12 
25. Smith NH, Upton P. 2012. Naming spoligotype patterns for the RD9-deleted lineage of the 226 
Mycobacterium tuberculosis complex; www.Mbovis.org. Infect Genet Evol 12:873-6. 227 
26. Lipworth S, Jajou R, de Neeling A, Bradley P, van der Hoek W, Maphalala G, Bonnet M, 228 
Sanchez-Padilla E, Diel R, Niemann S, Iqbal Z, Smith G, Peto T, Crook D, Walker T, van 229 
Soolingen D. 2019. SNP-IT tool for identifying subspecies and associated lineages of 230 
Mycobacterium tuberculosis complex. Emerg Infect Dis 25:482-488. 231 
27. Rahim Z, Thapa J, Fukushima Y, van der Zanden AGM, Gordon SV, Suzuki Y, Nakajima C. 232 
2017. Tuberculosis caused by Mycobacterium orygis in dairy cattle and captured monkeys in 233 
Bangladesh: A new scenario of tuberculosis in South Asia. Transbound Emerg Dis 64:1965-234 
1969. 235 
 236 
 o
n
 M
ay 13, 2019 by guest
http://aac.asm
.org/
D
ow
nloaded from
 
MTBC 3
4
5
6
7
8
9
10
11
12
13
1
)
M
.
c
a
n
e
tt
ii
(i
n
tr
in
s
ic
a
lly
re
s
is
ta
n
t
to
p
y
ra
z
in
a
m
u
d
e
)
2
)
M
.
c
a
n
e
tt
ii
(i
n
tr
in
s
ic
a
lly
re
s
is
ta
n
t
to
p
y
ra
z
in
a
m
u
d
e
)
/M
.
tu
b
e
rc
u
lo
s
is
3
)
M
.
a
fr
ic
a
n
u
m
/M
.
o
ry
g
is
/
M
.
p
in
ip
e
d
ii/
c
la
d
e
A
1
4
)
M
.
m
ic
ro
ti
5
)
M
.
c
a
p
ra
e
6
)
M
.
c
a
p
ra
e
/M
.
b
o
v
is
(n
o
t
in
tr
in
s
ic
a
lly
re
s
is
ta
n
t
to
p
y
ra
z
in
a
m
id
e
)
8
)
M
.
b
o
v
is
B
C
G
(i
n
tr
in
s
ic
a
lly
re
s
is
ta
n
t
to
p
y
ra
z
in
a
m
id
e
a
n
d
c
y
c
lo
s
e
ri
n
e
)
7
)
M
.
b
o
v
is
(i
n
tr
in
s
ic
a
lly
re
s
is
ta
n
t
to
p
y
ra
z
in
a
m
id
e
)
Clade A1: M. mungi, M. suricattae, Dassie bacillus, Chimpanzee bacillus
UC 2
CC 1
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